Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults

Brasilia University Hospital

Status and phase: Completed; Phase 3

Conditions: Hypotension; Bradycardia

Treatments: Drug: Remifentanil

Study type: Interventional

Funder types: Other

Identifiers

NCT03065309

TCC-Lara-2017

Details and patient eligibility

About

This study will find the median effective dose of remifentanil for rapid sequence intubation which avoids bradycardia and hypotension

Full description

Remifentanil is becoming popular for rapid sequence intubation because it has a fast onset and ultra-short half-life.

Remifentanil a potent opioid associated to bradycardia and hypotension at high doses.

Enrollment: 15 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Indication of anesthesia induction

Exclusion criteria

• Protocol violation
• Monitoring problems

Trial design

15 participants in 1 patient group

Single Arm

Experimental group

Description:

Patients will receive bolus dose of remifentanil before intubation

Treatment:

Drug: Remifentanil